About Us

Avista Pharma Solutions is a contract development, manufacturing, and testing organization that understands what it takes to rapidly advance products through every stage of development. With over 200,000 square feet of laboratory and manufacturing space in the U.S. and U.K., Avista Pharma offers a broad suite of scientifically differentiated services ranging from early stage discovery, API and Drug Product development and cGMP manufacturing to stand-alone analytical and microbiology testing support. Led by our broad experience and collaborative approach, we are committed to finding the shortest, most efficient path to success for our clients—success that goes beyond science.

Members of the Avista Pharma Executive Team

Patrick Walsh, CEO & Member of the Board of Directors

Patrick is an experiencedWeb-Walsh CEO whose leadership teams are recognized for their stellar performances and high growth achievements. He has extensive experience directing pharmaceutical manufacturing operations on a global scale in parenteral, API, specialty pharmaceutical, formulation, manufacturing and analytical contract development organizations. Patrick has served as Chairman, Non-Executive Chairman and a company Director in twelve (12) organizations as well as an Executive Advisor to private equity and venture capital firms.  At Avista Pharma Solutions (Avista Pharma), Patrick also serves as a member of the Board of Directors.


Prior to Avista Pharma, Patrick was CEO of AAIPharma Services, where he led the successful growth strategy culminating in the sale of the company for a 4.6 times return on invested capital.


Prior executive roles include CEO roles in several life science companies and President & COO of Gensia-Sicor. He started his career as a sales representative for Invenex Labs and LyphoMed.


He holds a degree in General Studies and resides in North Carolina with his wife and 3 children.


Eric Evans, Chief Financial Officer

Eric is a finance and operations executive with over thirty years of experience across both pharmaceutical and contract service sectors. Prior to joining Avista Pharma Solutions, he served as CFO at Mayne Pharma US, a $420 million US pharmaceutical company with three business units – Specialty Brands, Generics and Contract Development Services. Prior to Mayne Pharma US, he served as CFO of two other CDMOs: AAIPharma Services and Patheon Inc. He also held positions in the pharmaceutical industry as VP and Controller for Novartis Pharmaceuticals Corporation and VP and CFO of Sandoz Inc. Eric’s career includes leadership roles in a wide range of acquisitions and divestitures, business integrations, financings and ERP implementations.


Eric received his MBA from the Weatherhead School of Management at Case Western Reserve University in Cleveland, Ohio. He also earned a master’s degree from the University of Western Ontario in London, Canada and a bachelor’s degree from Queen’s University in Kingston, Canada.


Cathy Butler, Chief Information Officer

Cathy brings over 15 years of experience in IT leadership from across the pharmaceutical industry.  She joined Avista Pharma from Smith & Nephew, where she was a Vice President with IT global responsibilities.  Prior to Smith and Nephew, Cathy was head of IT for Mayne Pharma in Greenville, NC where she was responsible for a full ERP implementation, as well as implementations and/or upgrades for Master Control, Blue Mountain, Empower, Salesforce, and Tableau.  She also led that company’s packaging serialization project.  Prior to Mayne Pharma, Cathy held senior IT roles at Mylan, Hospira, and Novartis.  At Novartis, she was the IT Lead for the Holly Springs, NC vaccine manufacturing site during its construction and startup.  Her IT responsibilities included  the implementation of the core applications such as SAP, LIMS, ERP/MRP, Time Tracking, Calibration, Document Management and Training.


Cathy holds a Bachelor of Science in Bio-Chemistry and Master of Science in Information Systems from Marist College.


Ken Domagalski, Chief Operating Officer of CMC Operations

Web-DomagalskiKen has over 30 years in the pharmaceutical industry of which 20 years were with Teva Parenteral Medicines. Ken has served in various executive roles including Vice President of Quality, Vice President of Operations, and Vice President of Process Engineering & Validation. He has led global organizations with hands-on experience including validation of systems, equipment, cleaning, product and processes in support of facility startups and new product introductions.


During his tenure at Teva Parenteral Medicines, Ken led and/or provided significant direction in the build-out of a dedicated high potency facility, a facility for sterile suspensions as well as a facility for the manufacture of sterile emulsions. Ken also led automation efforts for the quality support systems as part of the facility and system design and enhancements.


Ken has led numerous successful FDA, EMEA, MCA and other international cGMP inspections.


Ken holds a B.S. in Biology and Life Sciences from Niagara University.


Members of the Avista Pharma Leadership Team

Eduardo Uribe, VP of Quality & Regulatory Compliance

Eduardo is a pharmaceutical industry executive with 30 years of experience.  Prior to joining Avista Pharma, he held quality management roles of increasing responsibility across the industry including Director of Quality at Gilead Sciences, Sr. Director of Manufacturing Quality Services at AAIPharma Services, and Sr. Director of Quality Operations at Irvine Pharmaceutical Services.  Most recently, Eduardo led his own consulting practice serving pharmaceutical and CDMO clients specializing in quality systems, PAI readiness, manufacturing and lab operations, validation, and vendor audits.  His experience designing and implementing quality systems spans oral and injectable dosage forms from small molecules to biologics.


Eduardo holds a B.S. in Biology from Kutztown University of Pennsylvania.


Rob Goshert, VP of Business Operations

Web-GoshertRob is a pharmaceutical industry veteran of 35 years with over 30 years of management experience. He has been instrumental in building teams, developing business plans and leading operations in global sales, marketing, project management, proposals, contracts, client services and manufacturing operations. Rob began his pharmaceutical career with Ciba-Geigy (now Novartis) before following his passion of guiding smaller companies to high-growth successes.


Rob’s experience includes influential positions at LyphoMed, Fujisawa, Gensia-Sicor and AAIPharma, all of which experienced explosive growth during his tenure.


Rob and his wife of 34 years are each graduates of Butler University in Indianapolis and are the proud parents of 2 young men.


Timothy Compton, VP of Sales

Web-ComptonTimothy is an industry professional with a successful track record in R&D, sales team management, business development and corporate marketing. Tim’s first 10 years of his career were in Research and Development (R&D) developing oncology diagnostics and advancing novel pain therapeutics with Atairgin Technologies and Kadmus Pharmaceuticals, respectively.  Following his successful tenure at the bench, Tim took on increasing roles of responsibility within Business Development at Baypoint Biosystems, Irvine Pharmaceutical Services and as Executive Director of Business Development at AAIPharma Services. He led the sales team at AAIPharma, which more than doubled annual sales and brought over 500 new clients to the company, and he led the company’s corporate marketing initiatives.


Tim holds a B.S. in Microbiology from Washington State University and is an active duty veteran of the U.S. Army.


Eric Kesslen, Ph.D., Site Director, Agawam Facility

EricEric is a pharmaceutical professional with over 19 years of experience in supporting pharmaceutical product development. Prior to his role at Avista Pharma, Eric built successful analytical development and microbiological teams that supported numerous national and international clientele at AAIPharma Services. In his tenure, he has held leadership roles in the implementation of quality management systems, ERP systems and electronic document control systems, and managed in high growth environments. A recognized expert in analytical and compendial matters, Eric currently serves on the USP Expert Panel for the Residual Solvents General Chapter 467 and the USP Expert Committee for Chemical Medicines Monographs.


Eric received his master’s and doctorate degrees in inorganic chemistry from the University of Rhode Island and his bachelor’s degree in chemistry from Arizona State University.


Stephen Watt, Ph.D., President, Solid Form Solutions

Stephen is a CRO and pharmaceutical industry professional having served as head of Solid Form Solutions since 2008. Prior to leading SFS, Stephen worked in the Solid Form Sciences Group at GSK and held leading roles in other CROs.


Stephen earned his Ph.D. in materials science from Heriot-Watt University and held a post-doctoral position under Profession Williams Jones at the prestigious Pfizer Institute for Pharmaceutical Materials Science, Cambridge University.



Members of the Board of Directors

David J. Parker

Dave, who has more than 15 years of private equity experience, joined Ampersand in 1994. Dave’s board seats have included Bako, NOVEX, Signature Genomics and Roadrunner. Prior to joining Ampersand, Dave spent five years consulting at Bain and Mercer and four years in corporate lending at Bank of Boston. He holds a B.A. in Government and Economics from Dartmouth and an M.B.A. from Wharton.  For additional information, see Ampersand Capital Partners.


Trevor L. Wahlbrink

Trevor joined Ampersand in 2012. Most recently he was an Associate at Morgan Keegan where he worked on a number of leveraged acquisitions and recapitalizations of middle market companies. Prior to Morgan Keegan, Trevor was at Covington Associates, a specialty investment bank, where he focused on healthcare M&A transactions. Trevor’s board seats have included Confluent, Elite One and ETE Medical. Trevor holds a M.S. and B.S. in Accounting and Finance from Boston College and is a CFA charterholder. For additional information, see Ampersand Capital Partners.


Mark J. Kontny, Ph.D.

Mark is currently an independent consultant and President of Kontny Solutions, LLC, where he provides consulting services across the Life Sciences industry. Mark utilizes his extensive business experience in pharmaceutical product development strategy and execution, providing and managing contract development and manufacturing outsourcing (CDMO) services, CDMO M&A assessment and drug product due diligence. Mark’s previous positions include President, Pharmaceutical Development Services and Chief Scientific Officer for Patheon, Divisional VP, Global Pharmaceutical and Analytical Sciences for Abbott Laboratories, SVP of R&D and Chief Scientist for Ventaira Pharmaceuticals, Sr. Director for Pharmacia/Monsanto/GD Searle and nearly ten years at Boehringer Ingelheim Pharmaceuticals. Mark has B.S., M.S. and Ph.D. degrees in Pharmacy from the University of Wisconsin-Madison. He has over 30 years of professional experience in pharmaceutical development, has contributed to over 30 new product approvals and utilizes his broad experience from both sides of the outsourcing table in his current consulting practice. Mark has 19 publications, over 65 external presentations and 18 patents or pending patent applications. Mark is also a board member for Grand River Aseptic Manufacturing and serves as an advisor to several biotechnology and life sciences companies.


As a member of the Board of Directors, Mark brings extensive expertise and industry experience in pharmaceutical product development services, NCE & NBE formulation and process development, physical/chemical and solid state input for drug candidate selection, drug delivery technologies, analytical technology development, release and stability testing, clinical supply manufacturing, preparation of CMC sections of regulatory dossiers, technology transfer and CMC team oversight.